CHICAGO, April 18, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the launch ...

Illumina and Tempus AI have partnered to drive clinical adoption of next-generation sequencing tests beyond oncology, the companies said Tuesday. The collaborators will combine Illumina’s ...

Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and ...

Illumina Inc. and Tempus AI, Inc., a technology company leading the adoption of AI to advance precision medicine and patient care, announced a collaboration to accelerate clinical adoption of ...

Tempus AI has launched an advisory board of oncology experts to provide guidance and strategic advice to the Chicago-based company on research, product development and clinical use of its AI ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Tempus AI Inc (NASDAQ:TEM) increased during the last reporting period, rising from 17.21M to 19.96M. This put 19.74% of the company's publicly available shares short. Short ...

Option Chain is currently not available. Nasdaq provides call and put options information of stocks. Financial analysts and individual investors can rely on the chain to gauge the stock's ...

Institutional Holdings information is filed by major institutions on form 13-F with the Securities and Exchange Commission. Major institutions are defined as firms or individuals that exercise ...

Illumina and Tempus AI have partnered to drive clinical adoption of next-generation sequencing tests beyond oncology, the companies said Tuesday. The collaborators will combine Illumina’s artificial ...